All News

Research costs are up 47% - and a new EU study analyses why

Entrepreneurs from the United Kingdom gained the most nominations at this year’s Academic Enterprise Awards. Three UK spin-outs are among the top 12 chosen to go through to final awards in Brussels on 21 February, 2012.

As China becomes a major generator of intellectual property, so it is becoming more committed to protecting IP and enforcing the law

The UK may have used its veto on treaty change, but it will support increased spending on R&D from 2014 – 2020, as proposed in Horizon 2020. Cutting agriculture subsidies could pay for this, Business Minister Vince Cable tells Science|Business

A Finnish liquid biofuels project has started a researcher exchange with the American Energy Biosciences Institute.

Scottish biologist Anne Glover, named EU Chief Scientific Advisor, will face major challenges to be a ‘voice of science’ in Brussels

A gathering of ‘innovation’ experts at an EU conference highlights the political importance of innovation. But what is it?

The EC’s research plan projects a tripling of the new agency’s innovation networks

Small companies attract special attention - and at least €6.8 billion - in the Commission’s new research plan

The European Commission has released its official proposal for Horizon 2020, the EU’s new research funding scheme. Science|Business presents a roundup of first reactions from the European capital.

The EU’s new funding plan promises a big drop in paperwork and bureaucracy for grant applicants and recipients - but the details will matter

A two-year political fight formally began in Brussels on 30 November with the publication of the European Commission’s plan for Horizon 2020, its omnibus R&D programme. It promises less red tape, broader benefits, and more jobs and economic growth – but is it too expensive?

In the US as in Europe, competition regulators are stepping up efforts to prevent pharmaceutical companies blocking the sale of generics

Investments in ehealth can pay off for patients and healthcare administrators, as a growing number of systems across Europe testify. Now is not the time to cut back on investment

The promise of accelerated approvals and higher pricing has persuaded pharmaceutical companies to break the deadlock in antibiotic R&D